CLINICAL LAB SCIENEC

476
INDEX
normalcy of, determination of,
259–260
reporting of, 242–246, 243f,
246f, 261
SDs in, 237–241, 239f
sensitivity in, 260
specificity in, 260
spread of data on scale in, 238
variance from mean, 238–239
Westgard rules, 244–245
Quality assurance (QA) programs,
233–236, 235t–236t
charts used in, 234–236,
235t–236t
elements of, 234
spectrophotometry for QC,
233–234
Quality control (QC)
in AST determination, 380–381
calculations in, 236
concepts related to, 236
in Hct determination, initial and
weekly measurements, 341
in HDL determination, 378
results of
analysis of, 247–248
out-of-range, steps in correction
of, 247–248
rejection of, indications for, 248
in specimen setup for isolation
and identification in
microbiology laboratory, 394
spectrophotometry for, 233–234
in Stanbio Enzymatic Glucose procedure,
375
terminology related to, 234–236,
235t–236t
for tests, 245
in total cholesterol determination,
378
in total protein determination,
372
Quality control (QC) charts, defined,
235t
Quality control (QC) programs, 232
defined, 235t
Quality improvement, 233
Quality management system, 233
Quality systems, 233
Quantitative pipettes, 192–195,
193f, 194f
Quantitative procedures, in immunology,
403
Quantitative tests, control limits for,
establishment of, 245–246,
246f
Quantity not sufficient (QNS), 290
R
Radioimmune assays, 416
Random access instruments, 365
Random error, 237, 367
defined, 235t
Range rule, 244
Rapid microbiology, technology in,
389–390, 389t
Rate (kinetic) reaction, explanation
of, 227
RBCs. See Red blood cell(s)
(RBCs)
Reaction(s)
of ABO blood groups, with anti-A
and anti-B sera, 418, 418t
antibody-antigen, 81–82
end-point, 364
in clinical chemistry procedures,
369, 369f
immune, principle, 401–402
kinetic, 364
explanation of, 227
kinetic rate, 378, 379f
postzone, 403
prozone, 403
rate, explanation of, 227
Reagent grade water, 180–181,
216–217
Reagent strip, 293, 293f, 294f
chemical testing of urine by, 298,
299f
chemistry report with normal
values, 300t
Record(s), medical. See Medical
records
Red blood cell(s) (RBCs)
abnormal, morphology of, 350f
in CSF, examination of, 319–321,
319f, 320f
described, 328, 348
evaluation of, characteristics of,
351t
morphology of, 348–352, 349f,
350f, 351t
equipment and supplies,
348–349
principles, 348, 349f
procedure, 349–351, 350f
reporting of results, 351–352,
351t
nucleated, 350f
plasma in, 419
reticulocytes in, 352–353, 354f
“washing” of, 419–420
Red blood cell (RBC) count, in CBC,
326
Red blood cell (RBC) indices, 328
Reed, W., 2
Reference laboratories, costs related
to, medical service costs impacted
by, 163–164
Refractometer, 221, 222f, 292f
Refrigerators, laboratory, 176–177,
177f, 177t
Registration
described, 45
of medical laboratory workers,
described, 39–40, 40t
Reimbursement, insurance and,
159–160
Renal tubular cell, 305f
Repeat testing, costs of, medical service
costs impacted by, 168
Reproducibility, in QA, 250–253,
251f
Resorption, tubular, 313
Reticulocyte(s). See also Reticulocyte
count, determination of
described, 352–353, 354f
Reticulocyte count
correction factor for, 355
determination of, 352–355, 354f
equipment and supplies, 353
principles, 352–353
procedure, 353–354, 353f
reporting of results, 354
Reverse grouping, by tube, 426–427,
427f. See also Immunohematology
(blood banking),
indirect (reverse) grouping
by tube
Reverse osmosis, 217–218
RF. See Rheumatoid factor (RF)
Rh blood type, 81–82
Rh factor, 418
Copyright 2010 Cengage Learning. All Rights Reserved. May not be copied, scanned, or duplicated, in whole or in part. Due to electronic rights, some third party content may be suppressed from the eBook and/or eChapter(s).
Editorial review has deemed that any suppressed content does not materially affect the overall learning experience. Cengage Learning reserves the right to remove additional content at any time if subsequent rights restrictions require it.